RecruitingNCT03297775

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

Sponsor

University of Colorado, Denver

Enrollment

750 participants

Start Date

Jun 22, 2017

Study Type

OBSERVATIONAL

Conditions

Rheumatoid Arthritis Interstitial Lung Disease

Summary

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Eligibility

Min Age: 45 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at patients with rheumatoid arthritis (RA) — a condition where the immune system attacks the joints — to find out who is at risk of also developing scarring or damage in the lungs, called interstitial lung disease (ILD). **You may be eligible if...** - You are 45 years old or older - You have been diagnosed with rheumatoid arthritis using standard medical criteria **You may NOT be eligible if...** - You are unable to give informed consent - You are pregnant - You already have a known diagnosis of interstitial lung disease - There is evidence your lung disease is caused by something other than RA Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.